Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab)

Trial Profile

Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab)

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Anterior uveitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Apr 2014 New trial record
    • 21 May 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top